Reports

Stephan Emmerth

Stephan Emmerth

PhD | Director Therapeutic Innovation and BaseLaunch


Tel. +41 61 295 50 17

stephan.notexisting@nodomain.comemmerth@baselarea.notexisting@nodomain.comswiss
report Life Sciences
Roche gains CE mark for lung cancer diagnostic

26.07.2017

Roche gains CE mark for lung cancer diagnostic

Basel-based pharmaceutical company Roche has obtained a CE mark for its diagnostic procedure, which identifies patients with non-small cell lung cancer (NSCLC), who are then eligible for treatment with the Novartis drug ZYKADIA.

The companion diagnostic VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody identifies the biomarker anaplastic lymphoma kinase (ALK), Roche explains in a press release. The inhibition of this biomarker can help shrink tumours in patients with non-small cell lung cancer (NSCLC) in a targeted way. NSCLC patients with this biomarker qualify for treatment with the Novartis drug ZYKADIA. This procedure is the first immunohistochemistry (IHC) test to be CE marked as a companion diagnostic for ZYKADIA.

In the press release, Ann Costello, Head of Roche Tissue Diagnostics, notes that the precise and personalised diagnostic is critical for the fight against non-small cell lung cancer, commenting that: “Expanded use of the VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody to identify non-small cell lung cancer patients with an ALK-positive mutation allows us to aid clinicians and their patients in identifying appropriate treatment options.”

Categories

Life Sciences
Cookies

BaselArea.swiss uses cookies to ensure you get the best service on our website.
By continuing to browse the site, you are agreeing to the use of cookies.

Ok